You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgocalciferol
Accession NumberDB00153  (APRD00426, NUTR00005)
Typesmall molecule
Groupsapproved, nutraceutical
Description

Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
ErgocalciferolNot AvailableNot Available
Vitamin D2Not AvailableNot Available
SaltsNot Available
Brand names
NameCompany
CalcidolNot Available
DeltalinNot Available
DrisdolNot Available
Brand mixtures
Brand NameIngredients
Calcimate Plus Calcium, Potassium, Magnesium and Vitamin DCalcium (Calcium Citrate, Calcium Malate) + Magnesium (Magnesium Oxide) + Potassium (Potassium Chloride) + Vitamin D2 (Ergocalciferol)
Calcium and Magnesium Citrate with Vitamin DCalcium (Calcium Citrate) + Magnesium (Magnesium Citrate) + Vitamin D (Ergocalciferol)
Calcium Magnesium 2:1 Tablets with Vitamin DCalcium (Calcium Citrate) + Magnesium (Magnesium Oxide) + Vitamin D2 (Ergocalciferol)
Centrum 8409Beta-Carotene + Biotin + Chromium (Chromic Chloride) + Copper (Cupric Oxide) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide) + Iron (Ferronyl) + Manganese (Manganese Sulfate) + Molybdenum (Sodium Molybdate) + Nicotinamide + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D2 (Ergocalciferol) + Vitamin E (Vitamin E Acetate) + Vitamin K1 (Phytonadione) + Zinc (Zinc Oxide)
Insur-All Vitamin SupplementBiotin + Choline Bitartrate + D-Pantothenic Acid + Inositol + Nicotinamide + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Ergocalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Mega Halibut Liver OilVitamin a (Halibut Liver Oil) + Vitamin D (Ergocalciferol)
Msb EssentialsBeta-Carotene + Biotin + Calcium (Calcium Citrate) + Choline Dihydrogen Citrate + Chromium (Chromic Chloride) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Inositol + Iodine (Potassium Iodide) + Iron (Ferrous Fumarate) + Magnesium (Magnesium Citrate) + Manganese (Manganese Hvp Chelate) + Methionine + Molybdenum (Sodium Molybdate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 + Vitamin B2 (Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Ergocalciferol) + Vitamin E (D-Alpha Tocopherol) + Zinc (Zinc Chloride)
Pre-NatalBeta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Citrate, Calcium Carbonate) + Chromium (Chromium Hvp Chelate) + Copper (Copper Hvp Chelate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide) + Iron (Iron Citrate) + Magnesium (Magnesium Hvp Chelate) + Manganese (Manganese Hvp Chelate) + Molybdenum (Molybdenum Hvp Chelate) + Nicotinamide + Potassium (Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Silicon (Silicon Dioxide) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin Hydrochloride, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxine 5' Phosphate) + Vitamin C (Calcium Ascorbate) + Vitamin D2 (Ergocalciferol) + Vitamin E (D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Hvp Chelate)
Super Thera-MBeta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Phosphate (Dibasic)) + Chloride (Potassium Chloride) + Chromium (Chromic Chloride) + Copper (Cupric Sulfate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Potassium Iodide, Kelp) + Iron (Ferrous Fumarate) + Magnesium (Magnesium Oxide) + Manganese (Manganese Sulfate) + Molybdenum (Sodium Molybdate) + Nicotinic Acid (Nicotinamide) + Phosphorus (Calcium Phosphate (Dibasic)) + Potassium (Potassium Chloride) + Selenium (Sodium Selenate) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D2 (Ergocalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc (Zinc Sulfate)
Timed Release Multi Vitamin with Chelated MineralsBeta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Hvp Chelate, Calcium Phosphate (Tribasic)) + Choline Bitartrate + Chromium (Chromium Hvp Chelate) + Copper (Copper Gluconate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Potassium Iodide, Kelp) + Iron (Iron Hvp Chelate, Ferrous Fumarate) + Magnesium (Magnesium Oxide, Magnesium Hvp Chelate) + Manganese (Manganese Hvp Chelate) + Nicotinamide + Potassium (Potassium Chloride, Potassium Citrate) + Selenium (Selenium Hvp Chelate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D (Ergocalciferol) + Vitamin E (D-Alpha Tocopheryl Acetate) + Zinc (Zinc Hvp Chelate)
Categories
CAS number50-14-6
WeightAverage: 396.6484
Monoisotopic: 396.33921603
Chemical FormulaC28H44O
InChI KeyMECHNRXZTMCUDQ-RKHKHRCZSA-N
InChI
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
IUPAC Name
(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
SMILES
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Mass Specshow(9.78 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassVitamin D and Derivatives
Direct parentVitamin D and Derivatives
Alternative parentsSesterterpenes; Cyclohexanols; Cyclic Alcohols and Derivatives; Polyamines
Substituentscyclohexanol; cyclic alcohol; secondary alcohol; polyamine; alcohol
Classification descriptionThis compound belongs to the vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Pharmacology
IndicationFor use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
PharmacodynamicsErgoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone.
Mechanism of actionActivated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2–5 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.
AbsorptionReadily absorbed from small intestine (proximal or distal), requires presence of bile salts.
Volume of distributionNot Available
Protein binding>99.8%
Metabolism

Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2.

SubstrateEnzymesProduct
Ergocalciferol
Not Available
25-Hydroxyvitamin D2-25-glucuronideDetails
Ergocalciferol
Not Available
Vitamin D2 3-glucuronideDetails
Ergocalciferol
Not Available
25-Hydroxyvitamin D2 25-(beta-glucuronide)Details
Route of eliminationNot Available
Half life19 to 48 hours (however, stored in fat deposits in body for prolonged periods).
ClearanceNot Available
ToxicityLD50 = 23.7 mg/kg (Orally in mice); LD50 = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 1.0
Blood Brain Barrier + 0.9428
Caco-2 permeable + 0.8323
P-glycoprotein substrate Substrate 0.6628
P-glycoprotein inhibitor I Inhibitor 0.7614
P-glycoprotein inhibitor II Non-inhibitor 0.8391
Renal organic cation transporter Non-inhibitor 0.796
CYP450 2C9 substrate Non-substrate 0.8432
CYP450 2D6 substrate Non-substrate 0.9003
CYP450 3A4 substrate Substrate 0.7362
CYP450 1A2 substrate Non-inhibitor 0.9046
CYP450 2C9 substrate Non-inhibitor 0.8924
CYP450 2D6 substrate Non-inhibitor 0.9519
CYP450 2C19 substrate Non-inhibitor 0.8784
CYP450 3A4 substrate Non-inhibitor 0.8142
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8163
Ames test Non AMES toxic 0.9401
Carcinogenicity Non-carcinogens 0.9169
Biodegradation Not ready biodegradable 0.9742
Rat acute toxicity 3.6931 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.8502
hERG inhibition (predictor II) Non-inhibitor 0.7513
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Sanofi aventis us llc
  • Orit laboratories llc
  • Sigmapharm laboratories llc
  • Strides arcolab ltd
  • Sun pharmaceutical industries inc
  • Banner pharmacaps inc
  • Chase chemical co lp
  • Everylife
  • Impax laboratories inc
  • Lannett co inc
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
Prices
Unit descriptionCostUnit
Ergocalciferol powder234.4USDg
Doral 15 mg tablet3.41USDtablet
Doral 7.5 mg tablet3.37USDtablet
Drisdol 50000 unit capsule2.34USDcapsule
Drisdol 8288 unit/ml Liquid0.48USDml
Vitamin d 400 unit softgel0.04USDsoftgel capsule
Longs vitamin d 400 unit tablet0.03USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point116.5 °CPhysProp
water solubility50 mg/LTOMLIN,C (1994)
logP7.3Not Available
Predicted Properties
PropertyValueSource
water solubility4.33e-04 g/lALOGPS
logP7.59ALOGPS
logP7.05ChemAxon
logS-6ALOGPS
pKa (strongest acidic)18.38ChemAxon
pKa (strongest basic)-1.3ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count1ChemAxon
hydrogen donor count1ChemAxon
polar surface area20.23ChemAxon
rotatable bond count5ChemAxon
refractivity128.89ChemAxon
polarizability50.73ChemAxon
number of rings3ChemAxon
bioavailability1ChemAxon
rule of fiveNoChemAxon
Ghose filterNoChemAxon
Veber's ruleYesChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraGC-MSMS/MSLC-MS1D NMR2D NMR
References
Synthesis Reference

Charles W. Bishop, Glenville Jones, Ronald L. Horst, Nicholas J. Koszewski, Joyce C. Knutson, Raju Penmasta, Robert M. Moriarty, Stephen Strugnell, Timothy A. Reinhardt, Liang Guo, Sanjay K. Singhal, Lei Zhao, “Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2.” U.S. Patent US5789397, issued March, 1992.

US5789397
General Reference
  1. DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. Pubmed
External Links
ResourceLink
KEGG DrugD00187
KEGG CompoundC05441
PubChem Compound5280793
PubChem Substance46505053
ChemSpider4444351
ChEBI28934
ChEMBLCHEMBL1536
Therapeutic Targets DatabaseDAP000291
PharmGKBPA449484
Drug Product Database2017598
RxListhttp://www.rxlist.com/cgi/generic/ergocalciferol.htm
Drugs.comhttp://www.drugs.com/cdi/ergocalciferol.html
PDRhealthhttp://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/vit_0265.shtml
WikipediaErgocalciferol
ATC CodesA11CC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(78.4 KB)
Interactions
Drug Interactions
Drug
CholecalciferolVitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
ColesevelamBile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
Food InteractionsNot Available

Targets

1. Vitamin D3 receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Vitamin D3 receptor P11473 Details

References:

  1. Carvallo L, Henriquez B, Olate J, van Wijnen AJ, Lian JB, Stein GS, Onate S, Stein JL, Montecino M: The 1alpha,25-dihydroxy Vitamin D3 receptor preferentially recruits the coactivator SRC-1 during up-regulation of the osteocalcin gene. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):420-4. Epub 2007 Jan 10. Pubmed
  2. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol. 2006 Oct;37(10):1268-78. Epub 2006 Jul 27. Pubmed
  3. Ewing AK, Attner M, Chakravarti D: Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes. Mol Endocrinol. 2007 Aug;21(8):1791-806. Epub 2007 May 22. Pubmed
  4. Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. Pubmed
  5. Straube S, Derry S, Moore RA, McQuay HJ: Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007771. Pubmed
  6. Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR: Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res. 2007 Dec;22 Suppl 2:V2-10. Pubmed
  7. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007 Jun 15;67(9):911-23. Pubmed
  8. Marks HD, Fleet JC, Peleg S: Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):513-6. Epub 2007 Jan 5. Pubmed
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Q07973 Details

References:

  1. Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. Pubmed
  2. Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. Pubmed
  3. Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. Pubmed
  4. Sakaki T: [Recent studies on vitamin D metabolizing enzymes] Clin Calcium. 2006 Jul;16(7):1129-35. Pubmed
  5. Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. Pubmed

2. 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial O15528 Details

References:

  1. Turunen MM, Dunlop TW, Carlberg C, Vaisanen S: Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res. 2007;35(8):2734-47. Epub 2007 Apr 10. Pubmed
  2. Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3. Pubmed
  3. Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. Pubmed
  4. Sakaki T: [Recent studies on vitamin D metabolizing enzymes] Clin Calcium. 2006 Jul;16(7):1129-35. Pubmed
  5. Inouye K, Sakaki T: Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179-94. Pubmed

3. Sterol 26-hydroxylase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sterol 26-hydroxylase, mitochondrial Q02318 Details

References:

  1. Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. Pubmed
  2. Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. Pubmed
  3. Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. Pubmed
  4. Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K: Metabolism of 2 alpha-propoxy-1 alpha,25-dihydroxyvitamin D3 and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab Dispos. 2005 Jun;33(6):778-84. Epub 2005 Mar 11. Pubmed
  5. Sakaki T: [Recent studies on vitamin D metabolizing enzymes] Clin Calcium. 2006 Jul;16(7):1129-35. Pubmed

4. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents. Pubmed

5. Vitamin D 25-hydroxylase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Vitamin D 25-hydroxylase Q6VVX0 Details

References:

  1. Ramos-Lopez E, Bruck P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K: CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):807-10. Epub 2007 Jan 16. Pubmed
  2. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K: CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Jul 2;. Pubmed
  3. Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2. Biochim Biophys Acta. 2006 Feb;1761(2):221-34. Epub 2006 Feb 2. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08